Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection by Edwards, Caitlin E. et al.
Swine acute diarrhea syndrome coronavirus replication
in primary human cells reveals potential susceptibility
to infection
Caitlin E. Edwardsa, Boyd L. Younta, Rachel L. Grahama, Sarah R. Leista, Yixuan J. Houa, Kenneth H. Dinnon IIIb,
Amy C. Simsc, Jesica Swanstroma, Kendra Gullyd, Trevor D. Scobeya, Michelle R. Cooleya, Caroline G. Curriea,
Scott H. Randelle, and Ralph S. Barica,b,f,1
aDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; bDepartment of Microbiology and Immunology, University
of North Carolina at Chapel Hill, Chapel Hill, NC 27599; cChemical and Biological Signatures Division, Pacific Northwest National Laboratory, Richland, WA
99354; dDepartment of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; eMarsico Lung Institute, University of
North Carolina at Chapel Hill, Chapel Hill, NC 27599; and fRapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina, Chapel Hill,
NC 27599
Edited by Peter Daszak, EcoHealth Alliance, New York, NY, and accepted by Editorial Board Member Diane E. Griffin August 18, 2020 (received for review
January 22, 2020)
Zoonotic coronaviruses represent an ongoing threat, yet the myriads
of circulating animal viruses complicate the identification of higher-
risk isolates that threaten human health. Swine acute diarrhea syn-
drome coronavirus (SADS-CoV) is a newly discovered, highly patho-
genic virus that likely evolved from closely related HKU2 bat
coronaviruses, circulating in Rhinolophus spp. bats in China and else-
where. As coronaviruses cause severe economic losses in the pork
industry and swine are key intermediate hosts of human disease
outbreaks, we synthetically resurrected a recombinant virus (rSADS-
CoV) as well as a derivative encoding tomato red fluorescent protein
(tRFP) in place of ORF3. rSADS-CoV replicated efficiently in a variety
of continuous animal and primate cell lines, including human liver
and rectal carcinoma cell lines. Of concern, rSADS-CoV also replicated
efficiently in several different primary human lung cell types, as well
as primary human intestinal cells. rSADS-CoV did not use human
coronavirus ACE-2, DPP4, or CD13 receptors for docking and entry.
Contemporary human donor sera neutralized the group I human
coronavirus NL63, but not rSADS-CoV, suggesting limited human
group I coronavirus cross protective herd immunity. Importantly,
remdesivir, a broad-spectrum nucleoside analog that is effective
against other group 1 and 2 coronaviruses, efficiently blocked
rSADS-CoV replication in vitro. rSADS-CoV demonstrated little, if
any, replicative capacity in either immune-competent or immunode-
ficient mice, indicating a critical need for improved animal models.
Efficient growth in primary human lung and intestinal cells implicate
SADS-CoV as a potential higher-risk emerging coronavirus pathogen
that could negatively impact the global economy and human health.
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One Health recognizes that human, animal, and environmentalhealth are tightly interconnected (1). In the 21st century, three
novel human and three novel swine coronaviruses (CoVs) have
emerged suddenly and spread globally, demonstrating a critical
need for strategies that identify higher risk zoonotic coronaviruses
(2). Contemporary human coronaviruses include four isolates (e.g.,
HCoV NL63, HCoV 229E, and HCoV OC43, HCoV HKU1) that
reside within the group 1b and group 2a subgroups, respectively,
and cause significant upper and lower respiratory infections in
children and adults (3). These viruses likely originated from strains
in bats, rodents, and bovine before the beginning of the 20th century
(3). More recently, highly pathogenic human coronaviruses include
the betacoronavirus subgenra Sarbecovirus severe acute respiratory
syndrome coronavirus (SARS-CoV) strains that emerged in China
in 2003 and the Merbecovirus Middle East respiratory syndrome
coronavirus (MERS-CoV) strains that emerged in the Middle East
in 2012. SARS-CoV and MERS-CoV cause an atypical pneumonia
that rapidly progresses to acute respiratory distress syndrome, with
fatalities rates of 10% and 35%, respectively (4, 5). While the
MERS-CoV outbreak is still ongoing throughout the Middle East
and Sub-Saharan Africa, heterogeneous SARS- and MERS-like
CoVs with human epidemic potential are circulating in bat species
in Southeast Asia and elsewhere (6–8). As these data forecast, a
new Sarbecovirus recently emerged in Wuhan, China in 2019
(SARS-CoV-2). As of September 2020, the rapidly expanding
outbreak has surpassed 31 million cases, many of whom have
progressed to respiratory failure, resulting in more than 972,000
deaths worldwide in the last 9 mo (see The Johns Hopkins University
Dashboard, https://gisanddata.maps.arcgis.com/apps/opsdashboard/
index.html#/bda7594740fd40299423467b48e9ecf6) (9). Clearly, the
cross-species transmission potential of zoonotic CoVs to humans
and other important domesticated species remains high as global
pathogens of concern (2, 10).
Over the past 80 y, several novel coronaviruses have caused ex-
tensive outbreaks and economic losses in swine, including transmis-
sible gastroenteritis virus (TGEV), porcine respiratory coronavirus
(PRCV), porcine epidemic diarrhea coronavirus (PEDV), porcine
hemagglutinating encephalomyelitis virus (PHEV), and porcine del-
tacoronavirus (PDCoV) (11–14). Between October 2016 and 2019,
Significance
The emergence of new human and animal coronaviruses de-
mand novel strategies that characterize the threat potential of
newly discovered zoonotic strains. We synthetically recovered
recombinant wild-type and derivative swine acute diarrhea
syndrome coronaviruses (SADS-CoVs) that express indicator
genes and characterized their growth, macromolecular bio-
synthesis, and replication efficiency in a variety of mammalian
cell lines, including primary human cells. The data demonstrate
that SADS-CoV has a broad host range and has inherent po-
tential to disseminate between animal and human hosts, per-
haps using swine as an intermediate species.
Author contributions: C.E.E., B.L.Y., S.R.L., and R.S.B. designed research; C.E.E., B.L.Y.,
S.R.L., Y.J.H., A.C.S., J.S., K.G., T.D.S., M.R.C., and C.G.C. performed research; S.H.R. con-
tributed new reagents/analytic tools; C.E.E., B.L.Y., R.L.G., S.R.L., K.H.D., A.C.S., J.S., and
R.S.B. analyzed data; and C.E.E. and R.S.B. wrote the paper.
The authors declare no competing interest.
This article is a PNAS Direct Submission. P.D. is a guest editor invited by the
Editorial Board.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
1To whom correspondence may be addressed. Email: rbaric@email.unc.edu.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/
doi:10.1073/pnas.2001046117/-/DCSupplemental.









several novel coronavirus outbreaks were described in swine herds
throughout China. Infection with the novel swine acute diarrhea
syndrome coronavirus (SADS-CoV) was associated with acute diar-
rhea and vomiting with 90% mortality rates in piglets less than 5 d of
age (10, 15–17). SADS-CoV is an alphacoronavirus most closely re-
lated to bat coronavirus HKU2, while also being distantly related to
other coronaviruses, such as HCoV 229E, HCoV NL63, and swine
coronavirus PEDV (15). Rhinolophus spp. bats in the vicinity of local
outbreaks had viruses (HKU2) with high sequence similarity to
SADS-CoV strains, demonstrating that SADS-CoV likely originated
from bats (10). The recent and rapid global dissemination of highly
pathogenic variants of PEDV and PDCoV highlights the critical One
Health threat associated with a newly emerged swine coronavirus (18,
19), and demonstrates a need for resources to understand the virus
and its pathogenic potential in mammals.
The goal of this study was to evaluate human susceptibility for
SADS-CoV cross-species transmission and replication. To ad-
dress this question, we synthesized a full-length infectious clone
and recovered wild-type and derivative recombinant (r)SADS-
CoV that expresses tomato red fluorescent protein (rSADS-CoV
tRFP). We used these viruses to study virus replication, tran-
scription programs, and gene expression in vitro. We also dem-
onstrated that SADS-CoV replicated efficiently in primary
human cells derived from both the lung and intestine, high-
lighting an intrinsic potential for cross-species transmission and
human susceptibility to infection. Although wild-type and IFN
receptor (IFNR)-immunodeficient mice were not susceptible, we
demonstrated the availability of a small-molecule inhibitor that
efficiently block SADS-CoV replication in vitro. While revealing
the threat potential of SADS-CoV to humans and the global
community, the reagents and models provide a critical infra-
structure to study the molecular and evolutionary programs that
promote virus cross-species transmission while providing for
potential intervention strategies designed to control the pan-
demic spread of SADS-CoV in swine and potentially humans.
Results
Assembly of SADS-CoV Full-Length cDNAs. SADS-CoV likely emerged
after multiple independent virus introductions from heterologous
bat coronavirus strains circulating in bat populations into swine in
China (10). We focused on the prototype SADS-CoV isolate
(GenBank, accession no. MG557844) (Fig. 1A and SI Appendix, Fig.
S7). In developing a SADS-CoV infectious clone, we synthesized a
panel of contiguous cDNAs spanning the entire SADS-CoV ge-
nome that could be restricted with endonucleases and ligated
in vitro to assemble genome-length cDNA (Fig. 1B) (20, 21). The
individual cDNAs were linked by unique restriction endonuclease
sites between neighboring fragments, namely BsmBI, SapI, and
BglI. BsmBI and SapI sites were introduced to each fragment ex-
ternally in the plasmid sequence and were lost following digestion
and ligation (22), whereas the BglI site is internal to the corre-
sponding fragments (Fig. 1C). The SADS-CoV A fragment contains
a T7 promoter at the 5′ end, and the SADS-CoV F fragments
terminates in a poly-A track at the 3′ end followed by a NotI re-
striction site. Each fragment (SADS-CoV A–F) was stable in
Escherichia coli and allowed for systematic and directional assembly
of the full-length SADS-CoV cDNA.
Following electroporation of recombinant rSADS-CoV genome-
length transcripts into Vero CCL-81 cells in combination with
SADS-CoV nucleocapsid (N) gene transcripts to enhance infectivity
(22–24), rSADS-CoV virus replication was demonstrated by the
presence of subgenomic length leader-containing RNA transcripts
in cultures at 24 and 48 h postinfection (hpi). Moreover, wild-type
virus produced both cytopathic effects and plaques in culture and
could be serially passaged in vitro (SI Appendix, Fig. S1). Impor-
tantly and like several other zoonotic coronaviruses (25), one-step
growth curves demonstrated efficient virus growth in swine LLC-
PK1 and primate Vero CCL-81 kidney cultures with virus titers
exceeding 106 plaque forming units (PFU)/mL, in the presence, but
not absence, of low levels of trypsin (10 μg/mL) (Fig. 2 A and B).
Recombinant viruses that encode indicator genes provide
tools to study virus host range, species specificity, and sensitivity
to small-molecule inhibitors. To generate recombinant SADS-
CoV indicator viruses, we replaced the accessory ORF encod-
ing nonstructural protein 3a (ORF3a) with the gene encoding
tRFP, noting that many downstream ORFs encode luxury
functions in the Coronaviridae, including the ORF3 proteins of
PEDV and HCoV NL63 (Fig. 1D) (23, 26, 27). Integrating tRFP
into the SADS-CoV genome (rSADS-CoV tRFP) allows for
real-time visualization of virus replication via fluorescence mi-
croscopy in living cells, providing a strong marker for productive
virus infection, subgenomic transcription, and replication. De-
spite the loss of ORF3a, rSADS-CoV tRFP replicated to titers
similar to wild-type rSADS-CoV, approaching ∼106 PFU/mL, in
LLC-PK1 cells and Vero CCL-81 cells following a single-cycle
growth curve over a 48-h time course (Fig. 2 A and B). tRFP
expression observed under a fluorescent microscope demon-
strated productive infections of LLC-PK1 and Vero CCL-81 cells
with SADS-CoV (Fig. 2D). Additionally, Northern blot analysis
was utilized to detect the predicted mRNAs that should be
expressed during SADS-CoV infection in vitro (Fig. 2E). These
data demonstrate that ORF3 is likely not essential for efficient
virus replication in vitro.
Alphaviruses like the highly attenuated, nonselect Venezuelan
equine encephalitis virus strain 3526 (VEE 3526) have been
engineered as replicons to express high concentrations of foreign
transgene proteins in cell culture and in animals (28). To eval-
uate SADS-CoV structural protein synthesis following infection,
we produced VEE 3526 replicon particles (VRP) expressing the
SADS-CoV N and spike (S) genes. Using mouse antisera from
mice infected with the VEE VRP expressing the SADS-CoV N
gene, we demonstrated extensive N protein expression in LLC-
PK1 cells via Western blotting (Fig. 2C). Additionally, CCL-81
cells infected with rSADS-CoV tRFP were stained using both N
and S antisera from vaccinated mice and images observed via
immunoflourescence assay (Fig. 3 D and E). Both N and S
proteins are clearly evident in the infected cultures.
SADS-CoV Species Specificity. Using the rSADS-CoV tRFP indi-
cator virus, we examined recombinant virus growth in different
hosts, including immortalized monkey, pig, cat, and human cells.
At 48 hpi, rSADS-CoV tRFP produced robust tRFP expression
that was detected in African green monkey Vero CCL-81, swine
LLC-PK1, and feline AK-D lung cells (Figs. 2D and 3A). Vero
CCL-81 and LLC-PK1 cells also displayed increased tRFP
fluorescence in the presence of trypsin, which was required for
adequate viral propagation (SI Appendix, Fig. S2). At 48 hpi,
viral infections were also detected in human cells via red fluo-
rescence, including liver (Huh7.5), intestine (CaCo2), stomach-
intestine (ST-INT), and colorectal tumor cells (HRT) (Fig. 3A),
including limited overlap with cell lines reported by others (29).
Importantly, rSADS-CoV tRFP growth in Huh7.5 cells was ro-
bust even in the absence of exogenous trypsin treatment, repli-
cating to titers of >105 PFU/mL (Fig. 3B).
Immortalized cells are often derived from cancers or encode
aberrant numbers of chromosomes, including extensive deletions
and duplications, resulting in the loss of many key innate im-
mune and other antiviral genes (30–32). Consequently, evaluating
zoonotic coronavirus infection potential and growth in primary
cells derived from humans provides a more realistic assessment of
potential human susceptibility (7, 8, 33). Importantly, primary hu-
man lung cells, including microvascular endothelial cells (MVE),
fibroblasts (FB), human nasal epithelial (HNE), and human airway
epithelial cells (HAE) were all susceptible to productive SADS-
CoV infection (Fig. 4 A–C and SI Appendix, Fig. S4A). While
SADS-CoV replicated most efficiently in MVE and FB cultures,
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Fig. 1. Spike phylogeny of representative coronaviruses and organization of the SADS-CoV wild-type and RFP infectious clones. (A) The S protein sequences
of selected coronaviruses were aligned and phylogenetically compared. Coronavirus genera are grouped by classic subgroup designations (1b, 2a–d, 4).
Sequences designated as 1b* (including SADS-CoV and related viruses) group with 1b viruses in proteins other than S. Sequences were aligned using free end
gaps with the Blosum62 cost matrix in Geneious Prime. The tree was constructed using the neighbor-joining method based on the multiple sequence
alignment, also in Geneious Prime. Numbers following the underscores in each sequence correspond to the GenBank accession number. The radial phylogram
was rendered for publication using Adobe Illustrator CC 2019. (B) The general arrangement of the SADS-CoV genome. Blue represents nonstructural proteins
ORF1a and ORF1b. Red represents structural proteins spike, envelope, membrane, and nucleocapsid. Green represents accessory proteins 3a, 7a, and 7b.
Yellow represents the untranslated region. (C) The full-length infectious clone was divided into six contiguous cDNAs flanked by either BsmBI (SADS-CoV
A–C), SapI (SADS-CoV D), BglI (SADS-CoV E–F) to allow for efficient assembly of the full-length SADS cDNA. BsmBI and SapI are not present in the viral genome
sequence but are introduced externally in the fragment plasmid sequence. SADS-CoV A (nucleotides 1 to 4,496), SADS-CoV B (nucleotides 4,497 to 8,996),
SADS-CoV C (nucleotides 8,997 to 13,496), SADS-CoV D (nucleotides 13,497 to 17,997), SADS-CoV E (nucleotides 17,998 to 22,892), and SADS-CoV F (nucle-
otides 22,893 to end). (D) General organization of SADS-CoV tRFP depicting the insertion of tRFP in place of NS3a.









growth in HNE and HAE cultures approached 105 PFU/mL
(Fig. 4 B and C and SI Appendix, Fig. S4A). Importantly, SADS-
CoV also replicated efficiently in primary human intestinal cells
(Fig. 4D and SI Appendix, Fig. S4B), replicating to titers of 105
PFU/mL over 96 hpi (Fig. 4F). As seen with other coronaviruses,
such as SARS-CoV-2 (34), SADS-CoV infection in primary cells is
donor dependent with replication efficiency varying between pa-
tients. SADS-CoV replication was validated by RT-PCR evidence
of N gene mRNA transcripts and for N gene protein expression by
Western blot in several primary cell lines (Figs. 2C, 3C, and 4 E
and G and SI Appendix, Fig. S3). These data demonstrate that the
host range of SADS-CoV is very broad, providing potential op-
portunities for spillover from bats to swine or to other economically
important intermediate or companion hosts, including humans
(35–37).
For many virus families, herd immunity to contemporary human
viruses can cross-neutralize and minimize the potential for zoonotic
virus cross-species transmission and emergence in nature (38–43).
To provide some guidance for potential future outbreak control,
we next tested whether human convalescent sera to related group 1
coronavirus HCoV NL63 could cross-neutralize SADS-CoV tRFP.
Treatment with several human coronavirus sera provided little if
any cross-neutralization of SADS-CoV in Huh7.5 cells. Under
identical conditions, the sera effectively neutralized another group
1b CoV, HCoV NL63 (Fig. 5 A and B). Additionally, we evaluated
the capacity of a broad-spectrum coronavirus nucleoside antiviral,
remdesivir, to inhibit rSADS-CoV tRFP replication in Huh7.5
Fig. 2. Growth of wild-type and tRFP SADS-CoV. Growth of SADS-CoV wild-type and tRFP infectious clones compared in Vero CCL-81 (A) and LLC-PK1 (B)
cultures. All supernatants were titered on Vero CCL-81 cells. Viral titers grew to mid-105 to 107 PFU/mL in these cell types, with the highest titers seen in Vero
CCL-81 cells. (C) Cultures of LLC-PK1 cells infected with SADS-CoV and protein lysates were run onWestern blots with and without trypsin for comparison. Cell
lysates were probed with antinucleocapsid antibodies from sera of mice immunized with VRP. N proteins (41.6 kDa) were present among both conditions. (D)
tRFP expression of Vero CCL-81 and LLC-PK1 cultures is shown at 10× magnification. By 36 h, cytopathic effect in Vero CCL-81 cultures was complete. (E)
Northern blot analysis of wild-type SADS and SADS tRFP for leader containing transcripts of known ORFs.
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cells. In a concentration-dependent manner, remdesivir efficiently
inhibited SADS-CoV replication, as evidenced by reduced tRFP
expression and reduced virus titers after treatment (Fig. 5C and SI
Appendix, Fig. S5).
SADS-CoV Receptor Interactions. During SARS-CoV and HCoV
NL63 infections, the S glycoprotein binds the human angiotensin
converting enzyme 2 (ACE-2) receptor to direct entry into the cell
(44). During MERS-CoV infection, the virus binds human dipep-
tidyl peptidase 4 (DPP4) as a receptor to mediate infection of
human cells (45), while TGEV and some related group I corona-
viruses use aminopeptidase N (APN or CD13) (46). Consequently,
we treated Huh7.5 cells with polyclonal antibodies against human
DPP4 or human APN (CD13) under conditions that block MERS
and HCoV 229E infection (47, 48). After 1 h, the cultures were
inoculated with SADS-CoV tRFP. Additionally, DBT cells
expressing human ACE-2 were tested for their ability to support
SADS-CoV tRFP replication. Using tRFP as a readout, we found
no evidence of altered viral infectivity and replication in Huh7.5 in
the presence of high concentrations of either antireceptor antibody,
and SADS-CoV did not replicate in DBT–ACE-2 cells (Fig. 6).
These data suggest that SADS-CoV does not use any of these known
coronavirus receptors for docking and entry into human cells.
In Vivo Mouse Model Availability. Previous studies have reported
that SADS-CoV replicates to low levels in wild-type laboratory
mice (29). To enhance this model, identify host functions that may
modulate SADS-CoV infection severity, and evaluate drug per-
formance, we inoculated type I/II IFNR-immunodeficient mice
with 1 × 105 PFU of SADS-CoV by either intraperitoneal injection
or oral gavage. Upon using qRT-PCR to detect genome-length
mRNA and the most abundant single-guide RNA 6, we noted
little, if any, evidence of reproducible or robust virus replication in
the liver, spleen, or various sections of the intestine at day 2 (SI
Appendix, Fig. S6A). In fact, only 1 of 12 animals had evidence of
low-level virus gene expression in multiple tissues. While a few other
samples contained sporadic, low-level SADS mRNA, the positive
tissues were not consistent across organs or mice and indicate a
nonproductive infection that fails to replicate, at best. In wild-type
BALB/c mice, we also saw little, if any, evidence of measurable
Fig. 3. Host range of SADS tRFP. (A) Cultures of human Huh7.5 liver, human Hs738.St/Int stomach-intestine, human colo-rectal HRT-18 tumor, Caco2, LaBo
kidney, and feline AK-D lung cells were infected with SADS tRFP. All cell types, with the exception of Caco2 and Huh7.5 cells, were cultured in the presence of
trypsin to enhance virus infectivity. Cultures were visualized at 48 hpi for fluorescence at 10× magnification. (B) Growth of SADS-tRFP in Huh 7.5 cells. (C)
Cultures of Huh7.5 cells were infected with SADS-CoV and lysed for analysis by Western blot. N protein has a molecular mass of ∼41.6 kDa. Immunofluo-
rescent images of Vero CCL-81 cells infected with mock or SADS-CoV tRFP virus and stained with mouse anti-N (D) or anti-S (E) sera. Cultures were fixed at
24 hpi and viral proteins were visualized by immunostaining with antisera isolated from VRP S or VRP N vaccinated mice. Scale bars represent 100 μm.









replication in vivo at day 2 postinfection (SI Appendix, Fig. S6B).
While IFNR-immunodeficient mice have been shown to enhance
the replication of other coronaviruses in vivo (49, 50), this defect
had no substantial positive effect on SADS-CoV growth under our
treatment conditions. These data are consistent with the interpre-
tation that SADS-CoV does not replicate efficiently in Mus mus-
culus domesticusmice and that most, if not all, of the positive signal
is arising from abortive infections or input virus. Thus, our data
argue that standard laboratory mouse models are clearly insufficient
to provide opportunities for studying viral pathological mechanisms
or in evaluating the performance of antivirals and vaccines.
Discussion
Coronaviruses, as well as other zoonotic virus families—such as
orthomyxoviruses, paramyxoviruses, enteroviruses, and filoviruses—
represent high-threat pathogens to One Health and the global
economy (51, 52). The recent emergence of novel human and
animal coronaviruses dictates the need for new strategies to
identify higher-risk strains that may seed future disease outbreaks.
Most emerging human and animal coronaviruses, including the
recently emerged SARS-CoV-2, probably originated from bats (3,
27, 53–55) and have the capacity to evolve and spread rapidly
across the globe (56–58). Contemporary human and swine strains
have become fully adapted to their hosts, although some retain the
capacity to replicate in bat cells (27). Using large numbers of bat





Fig. 4. Susceptibility of human primary cells to SADS-CoV. (A) Human FB
and MVE cells (n = 3, each) were infected with SADS-CoV. By 72 hpi, abun-
dant infection of both FB and MVE cells by SADS-RFP was observed. (B) HNE
cells from two donors (n = 3) were infected with SADS-RFP, demonstrating
comparable RFP infection by 72 hpi. (C) HAE cells were infected both
basolaterally and/or apically (donor 1) or apically (donor 2) and observed for
96 h or 72 h, respectively. (D) Human primary intestinal cultures (n = 2) were
infected with SADS-RFP and were observed for 96 hpi. All fluorescent images
were taken at 10× magnification. (E) qRT-PCR of genomic mRNA from pri-
mary human lung cells infected with SADS-CoV. Cultures from various codes
were averaged to determine amounts of genomic viral RNA. No detectable
viral signal was observed in mock-infected cultures from each cell type, as
indicated by the * representing half the limit of detection. Levels of viral
genome were determined in infected and mock cultures, relative to 18S ri-
bosomal RNA. (F) Virus samples were taken from primary intestinal cells
every 24 hpi, and growth determined by plaque assay. (G) RT-PCR of leader
containing transcripts, run in duplicate, indicate presence of SADS-CoV
mRNA in MVE, FB, and HAE cells.
Fig. 5. Neutralization and inhibition of SADS-CoV. Neutralization assays
were run using human CoV donor sera against SADS-CoV (A) and HCoV NL63
(B), a known human coronavirus. Very little, if any, neutralization of SADS
was seen compared to neutralization of HCoV NL63. (C) Remdesivir, a known
antiviral, inhibited SADS-CoV virus growth, indicating a potential thera-
peutic for possible human infection.
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studies argue that the α-CoVs have a much higher likelihood to
switch hosts within their natural bat reservoirs than the β-CoVs,
implying high spillover risk to other mammalian species (59). In
support, recent findings indicate that SADS-CoV swine outbreaks
have likely originated from multiple spillover events from exotic
bats in China, and may readily cycle between these species (10). In
this report, we demonstrate human susceptibility potential by
demonstrating efficient SADS-CoV infectivity and growth in pri-
mary human cells, derived from both the lung and intestine (33).
Moreover, efficient SADS-CoV replication in the primary intes-
tinal cells also support an earlier hypothesis that some emerging
bat coronaviruses may initially replicate efficiently in the human
alimentary track and stroma, before evolving efficient replication
phenotypes in the lung (25).
With increased access to global travel and frequent human-
to-human interaction, it is crucial to develop and utilize strate-
gies to understand the risk potential of emerging viruses to One
Health globally. In this study, we used metagenomics, bio-
informatics, synthetic genome design, and reverse genetics to re-
cover recombinant wild-type and derivative SADS-CoVs from
in silico sequence databases. Using this model, we studied virus
genome organization and expression patterns in infected cells and
evaluated the capacity of human serum and small-molecule in-
hibitors to impede SADS-CoV growth in vivo. The molecular
clone and work described herein expands upon a recently pub-
lished swine enteric alphacoronavirus molecular clone (60) by: 1)
Generating mutants that demonstrated a nonessential role for
ORF3 is virus growth in vitro; 2) the development of indicator
viruses, which revealed new insights into the broad host range; 3)
studying cross-group 1b neutralization; and 4) identifying SADS-
CoV susceptibility to a broad-spectrum nucleoside chain termina-
tor, remdesivir, which has been used to treat lethal Ebola infections
with some success (61). Additionally, remdesivir is effective at re-
ducing SARS-CoV-2 infection and has been cleared for emergency
use in treating COVID-19 patients (62, 63). Previous studies in our
laboratory and others have shown that remdesivir was broadly active
against alpha-, beta-, and gammacoronaviruses both in vitro and
in vivo (64–66). As SADS-CoV is highly susceptible to remdesivir
treatment in vitro, these findings support its potential use in the
event of possible future SADS-CoV or related HKU2 disease
outbreaks. In mouse models of human disease, remdesivir is very
effective at treating lethal SARS-CoV2 infection (67) and MERS-
CoV infection than combination lopinavir, ritonavir, and IFN-β
(68). In contrast to other reports, SADS-CoV replication in wild-
type mice was minimal at best. We noted little evidence of signifi-
cant or reproducible replication across animals or tissues at day 2,
indicating the need for a proper small-animal model for use in
in vivo antiviral or vaccine testing (SI Appendix, Fig. S5). Our in-
ability to enhance SADS-CoV growth in immunodeficient IFNR−/−
mice provide further evidence that the mouse is not a suitable
model for SADS-CoV pathogenesis, vaccine, or therapeutic studies,
revealing a vulnerability in global preparedness.
The emergence of PEDV in the United States and China was
associated with devastating economic losses in the swine industry
(69, 70). SADS-CoV is closely related to HKU2 alphacor-
onavirus of bats, which was first identified in Hong Kong and
Guangdong Province, China, in 2007 (15). Although SADS-CoV
S glycoprotein variation is limited across outbreaks, HKU2-like
strains are widely dispersed throughout Europe, Southeast Asia,
and elsewhere and encode diverse S glycoprotein genes that vary
by as much as 15% (Fig. 1A) (10, 71). Although speculative, one
or more of these diverse HKU2-related strains may also encode
broad host range or transmission potentials, like SADS-CoV,
enhancing the potential for animal and human outbreaks. The
development of a stable molecular clone that can be used to
recover wild-type and derivative recombinant viruses encoding
different HKU2 S glycoprotein genes provides a robust platform
to address this important One Health concern. Importantly,
SADS-CoV has caused severe disease outbreaks in herds vacci-
nated with attenuated PEDV, illustrating the inability of existing
swine PEDV vaccines to elicit protective immune responses
against this emerging pathogen (17). The major component of
protective immunity for coronaviruses usually targets the S gly-
coprotein and, to a lesser extent, the N protein (72). Given the
extensive amino acid differences between contemporary human
group 1b CoV and SADS-CoV S genes, it is not surprising that
human sera efficiently neutralized hCoV NL63, but not SADS-
CoV (Fig. 5 A and B). Taking these data together, we find that
the inability for PEDV vaccines and human polyclonal sera to
protect against the SADS-CoV suggest that little, if any, cross-
coronavirus herd immunity would exist to control the spread of
this new pathogen, especially in swine. As previous studies have
Fig. 6. Potential receptors for SADS-CoV. Huh7.5 cells were treated with antibody against DPP4 or CD13 and then infected with SADS-CoV GFP. When
compared to the untreated cultures, all cells and antibody treatment conditions did not block SADS-CoV entry or replication, suggesting that SADS-CoV is not
using a known coronavirus entry receptor. Control DBT and DBT cells expressing hACE-2 were also infected and shown to be not permissive for SARS-CoV 2
GFP growth. All fluorescent images were taken at 10× magnification.









demonstrated that alphavirus VRP vaccines encoding the N and
S proteins can provide protection against lethal SARS-CoV and
MERS-CoV infection and protect swine from PEDV infection
(73), the SADS VRP N and S VRP vaccines developed herein
may provide for similar opportunities for controlling SADS-CoV,
and perhaps other group 1b swine coronavirus infections (74).
The coronavirus S glycoprotein is usually cleaved into distinct
S1 and S2 polyproteins that include well-defined domains, in-
cluding the S1 N-terminal domain (NTD) and C-terminal do-
main (CTD) (75). In some coronaviruses, the NTD contains folds
that bind sugar residues, while the CTD encodes the receptor-
binding domain, which engages various receptors, such as ACE-2,
DPP4, CECAM1, and CD13 (75). SADS-CoV targeted a variety of
host cell types from multiple species, including those characterized
as of both human and nonhuman origin. The surprisingly broad host
range of SADS-CoV does not appear to be driven by ACE-2,
DPP4, or CD13 receptor usage, as antibodies targeting these re-
ceptors do not inhibit virus replication in human cells and over-
expression of the human ACE-2 receptor also did not promote
replication in mouse cells. As protease treatment enhances SADS-
CoV host range, the data are also consistent with extensive litera-
ture that argues that protease availability is also a key regulator of
coronavirus cross-species transmission (76–78). rSADS-CoV tRFP
replication in various immortalized human cells, including liver,
stomach, intestinal, and rectal tumor cells (Fig. 3A). However, a
group 1 CoV camel coronavirus that was closely related to HCoV
229E also showed efficient replication in human tumor cell lines,
but not in primary human lung airway cells, demonstrating the
critical importance of evaluating zoonotic virus species specificity in
primary cells (33). In contrast and in the absence of exogenous
proteases, SADS-CoV replicated efficiently in primary human en-
dothelial cells, primary lung fibroblasts cells, but growth in primary
human airway and nasal epithelial cells. These cells play critical
roles in maintaining lung architecture, compartmentalization, and
airway function (79). Lung fibroblasts also play a central role in the
homeostasis of the extracellular matrix and are effector cells during
injury repair, while the microvascular endothelium regulates vas-
cular homeostasis, as vascular leak can result in inefficient gas ex-
change in the lungs (80). In parallel, we showed efficient growth in
primary human intestinal cells, including high virus titers after in-
fection. Together, these data forge a compelling argument regard-
ing potential human susceptibility to SADS-CoV infections. Future
studies must focus on identifying the entry and species-specificity
mechanisms that regulate SADS-CoV cross-species transmission
and pathogenesis, as well as the potential array of evolutionary
pathways that could evolve to promote efficient replication in dif-
ferent human cells and tissues.
The emergence of the group 2b SARS-CoV-2 in Wuhan, China
SADS-CoV demonstrated the predictive utility of using primary
human lung cells, receptor interaction, and antigenic studies to
predict the preepidemic potential of novel zoonotic viruses, and
then use this recombinantly derived collection of viruses to iden-
tify readily available drugs for compassionate use (6–8, 66, 68).
SADS-CoV also has a broad host range and replicates efficiently
in primary human lung and intestinal cells. Due to the variability
in infection efficiency seen between various donors of human
primary cells, it is likely that in the case of a spillover, we would
see a range of SADS-CoV severity in human patients. Swine are
known amplifying hosts for several human pathogens, providing
an infrastructure for the possibility of future emergence events. To
date, there is no evidence of virus replication in humans (10).
However, the ability of SADS-CoV to replicate in human primary
cells indicates the potential for spillover of SADS-CoV into hu-
mans. With the 2019 reemergence of this virus in the swine pop-
ulation in China (81), continued surveillance of swine is critical.
Additionally, individuals in the swine industry should be regularly
evaluated for evidence of infection in order to reduce the potential
of outbreaks. Consistent with the phylogenetic distance in the S
glycoproteins (Fig. 1A), little, if any, significant levels of cross-
neutralizing human or swine herd immunity appear to exist between
the contemporary alphacoronavirus tested and the SADS-CoV.
While recognizing an unexplored potential for T cell contributions
and given this collection of phenotypes, we suggest the need for
continued One Health surveillance (82, 83), screening of swine
workers in outbreak settings, BSL3 containment and that the
development and testing of candidate vaccines and drugs should
be prioritized to protect the health of human populations as well
as economically important domesticated livestock.
Materials and Methods
Virus and Cells. The recombinant SADS-CoV and its RFP-expressing derivative
(SADS-CoV tRFP) were propagated in Vero CCL-81 and LLC-PK1 cells. All cells
were maintained prior to infection in complete DMEM media supplemented
with 10% serum, nonessential amino acids, sodium pyruvate, and 1% anti-
biotic. To generate virus stocks, cells were washed twice with PBS and cul-
tured in serum-free DMEM-H media supplemented with 8% tryptose
phosphate broth and 2.5 to 10 μg/mL trypsin and grown at 37 °C in a hu-
midified CO2 incubator. Samples were then titered by plaque assay on Vero
CCL-81 cells. To enhance viral growth and spread, 10 μg/mL trypsin was
added to the overlay for plaque assay. Growth curves were performed in
Huh7.5 and LLC-PK1 cells, and supernatants were titered on Vero CCL-81
cells as previously described (84, 85). Huh7.5 cells did not require additional
trypsin for viral growth and spread, although it is likely that the inoculum
used to perform the growth curves contained minimal levels of residual
trypsin. For growth curves of SADS-CoV tRFP, fluorescent foci were counted
to determine titer. Primary human airway epithelial cells, lung fibroblast,
and lung microvascular endothelial cells prepared as described previously
(86) were purchased from the Marsico Lung Institute, Tissue Procurement
and Cell Culture Core, University of North Carolina at Chapel Hill, and used
to evaluate SADS-CoV growth using previously described methods (84, 85).
The cells obtained from human lungs were approved by the University of
North Carolina at Chapel Hill Biomedical Institutional Review Board (pro-
tocol #03-1396). Two-dimensional primary human intestinal cells were de-
rived from human ileal crypts that form a continuous polarized epithelium
with proliferative and nonproliferative zones (87). All primary cells (lung and
intestinal) were infected with SADS-CoV tRFP diluted at 1:10 in PBS. Inocu-
lated cultures were incubated at 37 °C in a humidified CO2 incubator for 2 h
before washing with PBS. Viral titers were determined using apical washes
of airway ALI cultures, or apical media of intestinal cultures at appropriate
time points. All recombinant SADS-CoVs were maintained in a BSL3 labo-
ratory to enhance biosafety and all waste material was disinfected and
autoclaved prior to removal from the facility. All personnel were equipped
with fully protective Tyvek suits, double gloves, and a powered air-purifying
respirator, as previously described by our group (8).
Systematic Assembly of a Full-Length SADS-CoV cDNA. The SADS-CoV clone
was designed using the previously published sequence (10). Six contiguous
cDNAs (A–F) flanked by unique restriction endonuclease sites (BsmBI/SapI/
BglI) were purchased from BioBasic (Fig. 1). Breakpoints were designed to
maximize the stability of cloned fragments in bacteria as previously de-
scribed by our group (21–24). The fragments were digested, separated
through 0.8% agarose gels, visualized, excised, and purified using a QIA-
quick Gel Extraction Kit. The SADS-CoV cDNAs were ligated overnight at
4 °C, phenol/chloroform extracted, and precipitated. Full-length T7 RNA
transcripts were generated in vitro as described by the manufacturer with
modifications (21). RNA transcripts (wild-type or tRFP) were added to a Vero
CCL-81 cell suspension (8 × 106) in an electroporation cuvette, and four
electrical pulses of 450 V at 50 μF were distributed with a Gene Pulser II
electroporator (Bio-Rad). As previously published, N gene transcripts were
included during electroporation due to the increased infectivity of corona-
virus transcripts when incorporated (20, 21). Transfected cells were allowed
to recover at room temperature before incubating at 37 °C for 4 d in a
75-cm2 tissue culture flask. Viral progeny were passaged once in either Vero
CCL-81 or LLC-PK1 cells for 2 to 4 d and used to generate a virus stock for
future use (GenBank, accession no. MT039231).
Recombinant SADS-CoV tRFP Expression Construct. To generate a SADS-CoV
tRFP recombinant virus, the nonstructural ORF, NS3a, was replaced with tRFP
via generation of three PCR amplicons and ligation into the SADS F frag-
ment. One PCR amplicon was generated using primers SADS tRFP #1+ (5′-gtg
cattgttgctaaggacgg-3′) and SADS tRFP #2 rev (5′-nnnnnngctcttcttggacgtggac
cttttcaatctc-3′). A second PCR amplicon was generated using primers SADS
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tRFP #3+ (5′-nnnnnngctcttctccaataatggtgagcaagggcgaggag-3′) and SADS tRFP
#4 rev (5′-nnnnnngctcttcattacttgtacagctcgtccatg-3′). A third PCR amplicon was
generated using primers SADS tRFP #5+ (5′-nnnnnngctcttcgtaatactaacacacctt
ttgttggtatc-3′) and SADS tRFP #6 rev (5′-ggcgcaaagagtgacaatgg-3′). The three
amplicons were digested with SapI, as indicated in the primer sequences
above, and ligated. The ligation product was then digested with Bpu10I and
EciI prior to insertion into the SADS F plasmid. Recovery of recombinant viruses
encoding tRFP are as described previously (GenBank, accession no. MT039232)
(20, 21).
VRP Expressing SADS N and S Genes. The SADS N and S genes were cloned
separately into pVR21 3526 to generate VRPs, as previously described (28, 88).
Briefly, pVR21 is an expression vector carrying the VEE genome in which the
VEE structural genes are replaced by the SADS N or S gene following the 26S
promoter. The SADS N and S gene, with the deletion of 7 amino acids from
the C terminus, was PCR-amplified off the full SADS cDNA before insertion
into the pVR21 backbone. The SADS-pVR21 construct, a plasmid containing
the VEE 3526 envelope glycoproteins, and a plasmid containing the VEE
capsid protein were used to generate T7 RNA transcripts. The RNA tran-
scripts were then electroporated into BHK cells. VRP were harvested 48 h
later and purified via high-speed ultracentrifugation. Groups of 5- to
7-wk-old BALB/c mice (Jackson Labs) were then inoculated via footpad in-
jection with VRP expressing the SADS N protein. Mice were boosted at 21 d,
killed at 14 d postboost, and serum was collected for antibody against the
N protein.
Western Blot Analysis. To produce protein lysates for analysis byWestern blot,
infected cells were washed with 1× PBS and lysed in buffer containing 20 mM
Tris·HCl (pH 7.6), 150 mM NaCl, 0.5% deoxycholine, 1% nonidet P-40, 0.1%
SDS. After initial lysis and removal of nuclei, supernatants were added to an
equal volume of 10 mM EDTA and 0.9% SDS. Following lysis, samples were
incubated for 15 min at room temperature prior to use in Western blot.
Proteins were separated using a 7.5% polyacrylamide gel. For each sample,
protein lysate was mixed with 4× loading dye and heated to 95 °C for
10 min. Samples were loaded into the gel and separated by electrophoresis
in 1× running buffer at 110 V for 5 min, followed by 90 V for 65 min. Proteins
were transferred onto an Immuno-Blot polyvinylidene difluoride (PVDF)
membrane at 115 mA for 30 min using 1× dry transfer buffer. The mem-
branes were blocked in 1× PBS–Tween 20 (PBST)–5% milk at 4 °C overnight
with shaking. Membranes were then treated with primary antibody using
mouse anti-SADS nucleocapsid sera (1:250) and incubated at 37 °C for 2 h
with shaking. Membranes were washed three times with 1× PBST before
treatment with secondary antibody. Secondary antibody of goat anti-mouse
IgG HRP (1:5,000) and were incubated at room temperature for 1 h with
shaking. Membranes were washed six times with 1× PBST (5 min per wash)
and developed using LI-COR WesternSure PREMIUM Chemiluminescent
Substrate. Membranes were incubated at room temperature for 5 min be-
fore imaging was performed using the LI-COR C-DiGit blot scanner.
Northern Blot Analysis. Total RNA was extracted from icSADS or icSADS-tRFP
infected cells approximately 20 hpi using TRIzol Reagent. Messenger [poly(A)]
RNA was isolated from the total RNA using an Oligotex mRNA Mini Kit.
Messenger RNA (0.6 to 0.7 μg) was separated on an agarose gel and trans-
ferred to BrightStar-Plus membrane using a NorthernMax-Gly Kit. Blots were
hybridized with a biotin-labeled oligomer (5′-BiodT/CTTTGATTACTCCACCA-
CACCAGACA/BiodT-3′), then detected using a Chemiluminescent Nucleic Acid
Detection Module.
RT-PCR of Leader Containing Transcripts. RNA, isolated using TRIzol Reagent,
was reverse transcribed using a SuperScript II kit and random primers. PCR
was performed using a SADS leader primer (5′-GACTTTCCAGTCTACTCTTCTC-
3′) and a reverse primer in the N gene (5′-CGAGACTGTGAACGTGAAGC-3′).
In Vivo Infection of BALB/C and IFNR Mice. Ten-week-old BALB/c or IFN type I/II
knockout mice (IFNR) were infected with 1 × 105 PFU of SADS-CoV. IFNR mice
were infected either intraperitoneally or by oral gavage, and BALB/c mice
were infected intranasally or by oral gavage. Mice infected by all inoculation
routes were given 1 × 105 SADS-CoV per route. Mice were weighed daily,
and samples were harvested at 2 d postinfection, including the liver, spleen,
and intestines. Intestinal samples were harvested by section including duo-
denum, jejunum, ileum, and colon. RNA was extracted from each tissue
sample and qRT-PCR was run to determine the amount of viral RNA present
in each mouse and tissue. These experiments were approved by University of
North Carolina’s Insitutional Animal Care and Use Committee (IACUC).
Neutralization Assays with hCoV Sera. Neutralization assays were performed
using known hCoV sera against SADS-CoV tRFP and NL63 GFP, using methods
previously described (89). NL63 GFP was used as a hCoV expected to be
neutralized by human donor sera. SADS-CoV tRFP and NL63 GFP diluted to
105 PFU were incubated with sera from four donors at 1:2 serial dilutions for
1 h at 37 °C. All dilutions were performed in serum-free media containing
1% antibiotic. Poly-L-lysine treated 96-well plates seeded with Huh7.5 cells
were infected with each condition of virus and sera, as well as with PBS and
sera-free virus as controls, for 1 h at 37 °C for SADS-CoV tRFP and 32 °C for
NL63 GFP. Following infection, virus and sera was removed and cells were
washed twice with 1× PBS before overlaid with serum-free media. Cells were
imaged for fluorescence and percent neutralization was calculated using the
area of fluorescence.
Inhibition of SADS-CoV by Remdesivir. Poly-L-lysine–treated 96-well plates
seeded with Huh7.5 cells were infected with SADS-CoV tRFP diluted to 2 ×
105 PFU in the presence of a dose–response of remdesivir or DMSO for 1 h at
37 °C. Following infection, virus was removed, and cells were overlaid with
serum-free media containing DMSO or the dose–response of remdesivir.
Cells treated with DMSO, but not virus, were included as a negative control
to serve as the 100% inhibition marker. Cells were imaged for fluorescence
and percent inhibition was calculated using the area of fluorescence.
Biosafety. Due to the potential for human susceptibility to SADS-CoV in-
fection, we recommend that work with this virus continue to be done under
BSL3 conditions.
Data Availability. The sequences of recombinant SADS-CoV viruses have been
deposited in GenBank under (accession nos: MT039231 for rSADS-CoV
wild-type (90) and MT039232 for rSADS-CoV tRFP (91). All other study data
are included in the main text and SI Appendix.
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